The PCSK9 Patent dispute saw a landmark UPC ruling that reinstated Amgen’s antibody patent, clarified core principles on inventive step, sufficiency, and claim interpretation, and strengthened legal certainty for innovators developing advanced biologic therapies across the European pharmaceutical & biopharmaceutical landscape.
A visual breakdown of the BMW R 1300 GS, comparing the production bike to its patent design from matrix LED headlight to GS Flyline and chassis.
This case highlights how the exenatide patent filed by Amylin Pharmaceuticals led to a detailed examination of inventive step, therapeutic efficacy, and Section 3(d) objections, culminating in a significant Delhi High Court judgment in Nov. 2025
Recently, The High Court of Delhi delivered a judgment in FMC v. Natco, a case between FMC Corporation and others (“FMC group”) and Natco Pharma Limited (“Natco”).
In a landmark decision concerning SPC for Durvalumab, the District Court of The Hague upheld the Dutch Intellectual Property Office’s (IPO) refusal to grant a Supplementary Protection Certificate (SPC) for AstraZeneca’s cancer immunotherapy drug Durvalumab, marketed as Imfinzi®. Durvalumab is an anti-PD-L1 antibody used in treating various cancers, and the refusal of SPC status has … Read more
If you have ever wondered why some days feel more stressful than others even when you sleep well? In the recent development there’s exciting news from the world of health tech, Ultrahuman’s Next-Gen Wearables: Files Patent for Physiological Stress Monitoring System, introducing a smart real-time monitoring technology that tracks stress by analyzing your body’s natural … Read more
On Nov 5, 2025, the Patents Court handed down an important interim injunction decision in Dr Reddy’s Laboratories (UK) Ltd v Boehringer Ingelheim International GmbH, neutral citation EWHC 2834 (Pat). Michael Tappin KC, sitting as a Deputy Judge, granted interim relief restraining Dr Reddy’s from dealing in empagliflozin (the active in Jardiance) in the UK … Read more
A recent Delhi High Court judgment in Zeria Pharmaceutical Co. Ltd. vs. The Controller of Patents (C.A.(COMM.IPD-PAT) 452/2022) delivers a message to the pharmaceutical industry: a higher yield and greater purity are not enough to secure a patent in India. Zeria’s patent application for a novel intermediate compound was rejected by the Indian Patent Office, … Read more
UK Court of Appeal Judgment on Dapagliflozin Patent UK Court of Appeal Judgment: Dapagliflozin Patent In a recent landmark judgment, the UK Court of Appeal upheld the High Court’s April 2025 decision invalidating the UK equivalent patent of EP1506211B1 (expired on May 14, 2023) for Dapagliflozin and its associated Supplementary Protection Certificate (SPC) (Expiry Date: … Read more
